US5951974A
(en)
*
|
1993-11-10 |
1999-09-14 |
Enzon, Inc. |
Interferon polymer conjugates
|
GB9417742D0
(en)
*
|
1994-09-03 |
1994-10-19 |
Univ Nottingham |
Macrophage stimulating composition
|
US5738846A
(en)
*
|
1994-11-10 |
1998-04-14 |
Enzon, Inc. |
Interferon polymer conjugates and process for preparing the same
|
ATE262920T1
(de)
|
1995-11-02 |
2004-04-15 |
Schering Corp |
Kontinuierliche, niedrigdosierte zytokine- infusionstherapie
|
US5908621A
(en)
|
1995-11-02 |
1999-06-01 |
Schering Corporation |
Polyethylene glycol modified interferon therapy
|
TW517067B
(en)
*
|
1996-05-31 |
2003-01-11 |
Hoffmann La Roche |
Interferon conjugates
|
US20030190307A1
(en)
*
|
1996-12-24 |
2003-10-09 |
Biogen, Inc. |
Stable liquid interferon formulations
|
US6472373B1
(en)
*
|
1997-09-21 |
2002-10-29 |
Schering Corporation |
Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
|
US5981709A
(en)
*
|
1997-12-19 |
1999-11-09 |
Enzon, Inc. |
α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
|
US5985263A
(en)
*
|
1997-12-19 |
1999-11-16 |
Enzon, Inc. |
Substantially pure histidine-linked protein polymer conjugates
|
IL138221A0
(en)
*
|
1998-03-26 |
2001-10-31 |
Schering Corp |
Formulations for protection of peg-interferon alpha conjugates
|
US6180096B1
(en)
|
1998-03-26 |
2001-01-30 |
Schering Corporation |
Formulations for protection of peg-interferon alpha conjugates
|
EE05214B1
(et)
|
1998-04-28 |
2009-10-15 |
Applied Research Systems Ars Holding N.V. |
Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon
|
TWI277424B
(en)
*
|
1998-05-15 |
2007-04-01 |
Schering Corp |
Combination therapy for eradicating detectable NCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
|
ITMI981148A1
(it)
*
|
1998-05-22 |
1999-11-22 |
Therapicon Srl |
Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie
|
KR20010052622A
(ko)
*
|
1998-06-08 |
2001-06-25 |
프리돌린 클라우스너, 롤란드 비. 보레르 |
만성 씨형 간염을 치료하기 위한 폴리에틸렌글리콜-인터페론-알파 및 리바비린의 용도
|
US6783965B1
(en)
|
2000-02-10 |
2004-08-31 |
Mountain View Pharmaceuticals, Inc. |
Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
|
DK1588716T3
(da)
*
|
1998-08-06 |
2011-05-23 |
Mountain View Pharmaceuticals |
Peg-uratoxidase-konjugater og anvendelse deraf
|
PL206536B1
(pl)
|
1998-10-16 |
2010-08-31 |
Biogen Idec Inc |
Kompozycja, kompozycja farmaceutyczna glikozylowanego interferonu-beta-1a, zastosowanie kompozycji glikozylowanego interferonu-beta-1a, sposób in vitro przedłużania aktywności glikozylowanego interferonu-beta-1a
|
CA2343094A1
(en)
*
|
1998-10-16 |
2000-04-27 |
Biogen, Inc. |
Interferon-beta fusion proteins and uses
|
US6824768B2
(en)
*
|
1998-12-18 |
2004-11-30 |
Schering Corporation |
Ribavirin-pegylated interferon alfa induction HCV combination therapy
|
JP2000256211A
(ja)
*
|
1999-03-02 |
2000-09-19 |
Schering Plough Corp |
Hiv治療薬
|
US6923966B2
(en)
*
|
1999-04-08 |
2005-08-02 |
Schering Corporation |
Melanoma therapy
|
ES2319776T3
(es)
|
1999-04-08 |
2009-05-12 |
Schering Corporation |
Terapia de melanoma.
|
US6605273B2
(en)
|
1999-04-08 |
2003-08-12 |
Schering Corporation |
Renal cell carcinoma treatment
|
PE20010288A1
(es)
|
1999-07-02 |
2001-03-07 |
Hoffmann La Roche |
Derivados de eritropoyetina
|
EP1224939A4
(en)
|
1999-10-12 |
2005-01-12 |
Santen Pharmaceutical Co Ltd |
INTERFERON-BASED COMPLEX AND ITS USE IN MEDICINE
|
TR200101086A3
(da)
*
|
1999-10-15 |
2001-08-21 |
|
|
US7230081B1
(en)
|
1999-11-12 |
2007-06-12 |
Maxygen Holdings, Ltd. |
Interferon gamma conjugates
|
PL356007A1
(en)
*
|
1999-11-12 |
2004-05-31 |
Maxygen Holdings Ltd |
Interferon gamma conjugates
|
HUP0203751A3
(en)
|
2000-01-10 |
2005-01-28 |
Maxygen Holdings Ltd Redwood C |
G-csf conjugates
|
EP1908477A3
(en)
*
|
2000-01-24 |
2008-06-11 |
Schering Corporation |
Combination of temozolomide and pegylated interferon-alpha for treating cancer
|
EP1251866A1
(en)
*
|
2000-01-24 |
2002-10-30 |
Schering Corporation |
Combination of temozolomide and pegylated interferon-alpha for treating cancer
|
ATE428445T1
(de)
|
2000-02-11 |
2009-05-15 |
Bayer Healthcare Llc |
Gerinnungsfaktor vii oder viia konjugate
|
EP1263457A2
(en)
*
|
2000-03-09 |
2002-12-11 |
Schering Corporation |
Hiv immune adjuvant therapy
|
US20080248544A1
(en)
*
|
2000-12-14 |
2008-10-09 |
Murray Christopher J |
Methods And Compositions For Grafting Functional Loops Into A Protein
|
US20030049689A1
(en)
*
|
2000-12-14 |
2003-03-13 |
Cynthia Edwards |
Multifunctional polypeptides
|
US20030068792A1
(en)
*
|
2000-12-14 |
2003-04-10 |
Yiyou Chen |
Targeted enzymes
|
US20030147874A1
(en)
*
|
2000-12-14 |
2003-08-07 |
Volker Schellenberger |
Targeted enzyme prodrug therapy
|
RU2003128955A
(ru)
|
2001-02-27 |
2005-04-10 |
Максиген Апс (Dk) |
Новые интерферон бета-подобные молекулы
|
US6958388B2
(en)
|
2001-04-06 |
2005-10-25 |
Maxygen, Aps |
Interferon gamma polypeptide variants
|
US7038015B2
(en)
*
|
2001-04-06 |
2006-05-02 |
Maxygen Holdings, Ltd. |
Interferon gamma polypeptide variants
|
UA78726C2
(en)
|
2001-11-01 |
2007-04-25 |
Sciclone Pharmaceuticals Inc |
Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
|
US20050095224A1
(en)
*
|
2001-12-07 |
2005-05-05 |
Ramachandran Radhakrishnan |
Compositions and method for treating hepatitis virus infection
|
CA2952488C
(en)
|
2002-01-18 |
2019-05-07 |
Biogen Ma Inc. |
Polyalkylene glycol with moiety for conjugating biologically active compounds
|
DE10209821A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung von Proteinen an ein modifiziertes Polysaccharid
|
TW200400818A
(en)
|
2002-05-21 |
2004-01-16 |
Wyeth Corp |
Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus
|
PT1517710E
(pt)
|
2002-06-21 |
2011-07-08 |
Novo Nordisk Healthcare Ag |
Glicoformas do factor vii peguilado
|
CN100348607C
(zh)
|
2002-06-28 |
2007-11-14 |
埃迪尼克斯(开曼)有限公司 |
用于治疗黄病毒科病毒感染的2’和3’-核苷前药
|
WO2004005341A2
(en)
*
|
2002-07-03 |
2004-01-15 |
Maxygen Holdings Ltd. |
Full-length interferon gamma polypeptide variants
|
CN100337689C
(zh)
*
|
2002-07-24 |
2007-09-19 |
弗·哈夫曼-拉罗切有限公司 |
聚亚烷基二醇酸加合物
|
JP4459810B2
(ja)
*
|
2002-08-14 |
2010-04-28 |
マクロジェニクス,インコーポレーテッド |
FcγRIIB特異的抗体とその利用法
|
US8044180B2
(en)
*
|
2002-08-14 |
2011-10-25 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8946387B2
(en)
*
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8968730B2
(en)
*
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8193318B2
(en)
*
|
2002-08-14 |
2012-06-05 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US20040136955A1
(en)
*
|
2002-09-05 |
2004-07-15 |
Barker Nicholas P |
Modified asialo-interferons and uses thereof
|
US20040062748A1
(en)
|
2002-09-30 |
2004-04-01 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
US8129330B2
(en)
|
2002-09-30 |
2012-03-06 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
CN100501400C
(zh)
|
2002-11-25 |
2009-06-17 |
希克龙制药公司 |
使用α胸腺素防护辐射损伤的方法
|
RS20050501A
(en)
*
|
2002-12-26 |
2007-08-03 |
Mountain View Pharmaceuticals Inc., |
Polymer conjugates of cytokines,chemokines,growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
|
CA2511814C
(en)
*
|
2002-12-26 |
2015-02-17 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates of interferon-beta with enhanced biological potency
|
US7960512B2
(en)
*
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
EP1587540B1
(en)
*
|
2003-01-09 |
2021-09-15 |
MacroGenics, Inc. |
IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
|
US20070077225A1
(en)
*
|
2003-02-28 |
2007-04-05 |
Blatt Lawrence M |
Continuous delivery methods for treating hepatitis virus infection
|
BRPI0419345B8
(pt)
*
|
2003-05-30 |
2021-05-25 |
Gilead Pharmasset Llc |
uso do (2r)-2-desoxi-2-flúor-2-c-metil nucleosídeo e de uma composição farmacêutica que o compreende
|
WO2005014655A2
(en)
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein
|
GB0320638D0
(en)
|
2003-09-03 |
2003-10-01 |
Novartis Ag |
Organic compounds
|
EP1673387B1
(en)
|
2003-10-10 |
2010-09-15 |
Novo Nordisk A/S |
Il-21 derivatives
|
TW201245229A
(en)
|
2003-10-14 |
2012-11-16 |
Hoffmann La Roche |
Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
|
EP2641611A3
(en)
|
2003-10-17 |
2013-12-18 |
Novo Nordisk A/S |
Combination therapy
|
JP4982183B2
(ja)
*
|
2003-12-12 |
2012-07-25 |
ジェネンコー・インターナショナル・インク |
Cab分子
|
WO2005074546A2
(en)
|
2004-02-02 |
2005-08-18 |
Ambrx, Inc. |
Modified human growth hormone polypeptides and their uses
|
US20090214472A1
(en)
*
|
2004-03-01 |
2009-08-27 |
Enzon Pharmaceuticals Inc. |
Interferon-beta polymer conjugates
|
DE602005023138D1
(de)
|
2004-04-15 |
2010-10-07 |
Genencor Int |
Anti-cea scfv-beta-lactamase konstrukte (cab moleküle) in adept
|
WO2005115452A2
(en)
*
|
2004-04-16 |
2005-12-08 |
Macrogenics, Inc. |
Fcϝriib-specific antibodies and methods of use thereof
|
AU2005244058B2
(en)
*
|
2004-05-10 |
2011-07-28 |
Macrogenics, Inc. |
Humanized FcgammaRIIB specific antibodies and methods of use thereof
|
KR101699142B1
(ko)
|
2004-06-18 |
2017-01-23 |
암브룩스, 인코포레이티드 |
신규 항원-결합 폴리펩티드 및 이의 용도
|
US20080233100A1
(en)
*
|
2004-06-30 |
2008-09-25 |
Yiyou Chen |
Targeted enzymes
|
CN101023094B
(zh)
*
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
JP4971160B2
(ja)
|
2004-08-12 |
2012-07-11 |
シェーリング コーポレイション |
安定するpeg化インターフェロン処方物
|
RU2433124C2
(ru)
|
2004-09-14 |
2011-11-10 |
Фармассет, Инк. |
Способ получения 2'-фтор-2'-алкилзамещенных или других замещенных рибофуранозилпиримидинов и пуринов и их производных
|
CA2587766A1
(en)
|
2004-11-10 |
2007-03-01 |
Macrogenics, Inc. |
Engineering fc antibody regions to confer effector function
|
US20080044400A1
(en)
*
|
2004-12-09 |
2008-02-21 |
Volker Schellenberger |
Targeted enzyme prodrug therapy
|
CN101087875B
(zh)
|
2004-12-22 |
2012-08-22 |
Ambrx公司 |
氨酰基-tRNA合成酶的组合物及其用途
|
US7816320B2
(en)
|
2004-12-22 |
2010-10-19 |
Ambrx, Inc. |
Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
|
NZ555206A
(en)
|
2004-12-22 |
2010-09-30 |
Ambrx Inc |
Methods for expression and purification of recombinant human growth hormone
|
US7939496B2
(en)
|
2004-12-22 |
2011-05-10 |
Ambrx, Inc. |
Modified human growth horomone polypeptides and their uses
|
US7365127B2
(en)
*
|
2005-02-04 |
2008-04-29 |
Enzon Pharmaceuticals, Inc. |
Process for the preparation of polymer conjugates
|
MX2007012547A
(es)
|
2005-04-11 |
2008-03-11 |
Savient Pharmaceuticals Inc |
Formas variantes de urato oxidasa y uso de las mismas.
|
DK1877102T3
(da)
|
2005-04-28 |
2014-07-21 |
Danisco Us Inc |
Tab-molekyler
|
CA2609205A1
(en)
|
2005-06-03 |
2006-12-14 |
Ambrx, Inc. |
Improved human interferon molecules and their uses
|
JP5335422B2
(ja)
|
2005-06-17 |
2013-11-06 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
少なくとも1つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化
|
JP2008546708A
(ja)
|
2005-06-17 |
2008-12-25 |
ノバルティス アクチエンゲゼルシャフト |
Hcvにおけるサングリフェリンの使用
|
TW200722104A
(en)
*
|
2005-06-20 |
2007-06-16 |
Pepgen Corp |
Low-toxicity, long-circulating human interferon-α analogs
|
US7695710B2
(en)
*
|
2005-06-20 |
2010-04-13 |
Pepgen Corporation |
Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
|
EP2305697A3
(en)
|
2005-07-25 |
2011-07-27 |
Intermune, Inc. |
Macrocyclic inhibitors of Hepatitis C virus replication
|
US8217147B2
(en)
|
2005-08-10 |
2012-07-10 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
NZ568135A
(en)
|
2005-10-11 |
2011-06-30 |
Array Biopharma Inc |
Macrocyclic compounds and methods for inhibiting hepatitis C viral replication
|
PT2339014E
(pt)
|
2005-11-16 |
2015-10-13 |
Ambrx Inc |
Métodos e composições compreendendo aminoácidos não-naturais
|
CA2644903A1
(en)
*
|
2006-03-10 |
2007-09-20 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant heavy chains and methods of using same
|
NZ571826A
(en)
|
2006-04-11 |
2012-01-12 |
Novartis Ag |
HCV/HIV inhibitors and their uses
|
US20080096819A1
(en)
|
2006-05-02 |
2008-04-24 |
Allozyne, Inc. |
Amino acid substituted molecules
|
US7632492B2
(en)
|
2006-05-02 |
2009-12-15 |
Allozyne, Inc. |
Modified human interferon-β polypeptides
|
RU2008145084A
(ru)
|
2006-05-24 |
2010-06-27 |
Ново Нордиск Хелс Кеа Аг (Ch) |
Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
|
ES2489646T3
(es)
|
2006-05-26 |
2014-09-02 |
Macrogenics, Inc. |
Anticuerpos humanizados específicos a Fc gamma RIIB y sus métodos de uso
|
EP2032159B1
(en)
*
|
2006-06-26 |
2015-01-07 |
MacroGenics, Inc. |
Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
|
HUE030269T2
(en)
|
2006-06-26 |
2017-04-28 |
Macrogenics Inc |
FC RIIB-specific antibodies and methods for their use
|
EP2061878B1
(en)
|
2006-09-08 |
2014-01-08 |
Ambrx, Inc. |
Hybrid suppressor trna for vertebrate cells
|
DK2615108T3
(da)
|
2006-09-08 |
2017-01-30 |
Ambrx Inc |
Modificeret humant plasmapolypeptid eller fc scaffolds og deres anvendelser
|
NZ574960A
(en)
|
2006-09-08 |
2012-02-24 |
Ambrx Inc |
Suppressor trna transcription in vertebrate cells
|
DE602007010499D1
(de)
*
|
2006-09-29 |
2010-12-23 |
Canji Inc |
Verfahren und zusammensetzungen für gentherapie
|
US20080112961A1
(en)
*
|
2006-10-09 |
2008-05-15 |
Macrogenics, Inc. |
Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
|
EP2097068B1
(en)
*
|
2006-11-24 |
2013-09-04 |
Cadila Healthcare Limited |
Formulations of peg-interferon alpha conjugates
|
WO2008140603A2
(en)
|
2006-12-08 |
2008-11-20 |
Macrogenics, Inc. |
METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
BRPI0809583B1
(pt)
|
2007-03-30 |
2022-02-22 |
Ambrx, Inc |
Polipeptídeo fgf-21 modificado, composição compreendendo o mesmo, método para produzir o referido polipetídeo fgf-21 e célula compreendendo um polinucleotídeo
|
US8114630B2
(en)
|
2007-05-02 |
2012-02-14 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
US7625555B2
(en)
|
2007-06-18 |
2009-12-01 |
Novagen Holding Corporation |
Recombinant human interferon-like proteins
|
CA2707840A1
(en)
|
2007-08-20 |
2009-02-26 |
Allozyne, Inc. |
Amino acid substituted molecules
|
JPWO2009028573A1
(ja)
|
2007-08-27 |
2010-12-09 |
国立大学法人名古屋大学 |
血液凝固障害におけるリバビリンの利用
|
CA2702637A1
(en)
|
2007-10-22 |
2009-04-30 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
NZ584825A
(en)
|
2007-11-20 |
2013-03-28 |
Ambrx Inc |
Modified insulin polypeptides and their uses
|
EP3103880A1
(en)
|
2008-02-08 |
2016-12-14 |
Ambrx, Inc. |
Modified leptin polypeptides and their uses
|
TW200946541A
(en)
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
PL2247304T3
(pl)
|
2008-04-02 |
2017-01-31 |
Macrogenics, Inc. |
Przeciwciała specyficzne wobec HER2/neu oraz sposoby ich zastosowania
|
MX2010010387A
(es)
|
2008-04-02 |
2010-10-15 |
Macrogenics Inc |
Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos.
|
EP2282770B1
(en)
*
|
2008-06-04 |
2018-03-07 |
MacroGenics, Inc. |
Antibodies with altered binding to fcrn and methods of using same
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
AU2009268841B2
(en)
|
2008-07-08 |
2014-02-06 |
Board Of Regents, The University Of Texas System |
Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (STATS)
|
CN102159230A
(zh)
|
2008-07-23 |
2011-08-17 |
Ambrx公司 |
经修饰的牛g-csf多肽和其用途
|
CN102232085A
(zh)
|
2008-09-26 |
2011-11-02 |
Ambrx公司 |
修饰的动物促红细胞生成素多肽和其用途
|
PL2337846T3
(pl)
|
2008-09-26 |
2018-06-29 |
Ambrx, Inc. |
Mikroorganizmy i szczepionki z replikacją zależną od nie-naturalnych aminokwasów
|
AR074897A1
(es)
|
2008-12-23 |
2011-02-23 |
Pharmasset Inc |
Fosforamidatos de nucleosidos
|
EP2376515A1
(en)
|
2008-12-23 |
2011-10-19 |
Pharmasset, Inc. |
Synthesis of purine nucleosides
|
SG172361A1
(en)
|
2008-12-23 |
2011-07-28 |
Pharmasset Inc |
Nucleoside analogs
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
TWI576352B
(zh)
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
CZ2011827A3
(cs)
|
2009-06-25 |
2012-09-26 |
Savient Pharmaceuticals, Inc. |
Zpusoby a sady pro predpovídání rizika reakce na infuzi a ztráty odezvy zpusobené protilátkami, monitorováním kyseliny mocové v séru behem lécby pegylovanou urikázou
|
WO2011014882A1
(en)
|
2009-07-31 |
2011-02-03 |
Medtronic, Inc. |
CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
|
TR201804897T4
(tr)
|
2009-10-07 |
2018-06-21 |
Macrogenics Inc |
Fukosi̇lasyon ölçüsünün deği̇şi̇mleri̇nden dolayi geli̇şmi̇ş efektör i̇şlevi̇ sergi̇leyen fc bölgesi̇ni̇ i̇çeren poli̇pepti̇tler ve bunlarin kullanimlarina yöneli̇k yöntemler
|
WO2011053617A1
(en)
|
2009-10-30 |
2011-05-05 |
Boehringer Ingelheim International Gmbh |
Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
|
KR20120123365A
(ko)
|
2009-12-21 |
2012-11-08 |
암브룩스, 인코포레이티드 |
변형된 돼지 소마토트로핀 폴리펩티드 및 이의 용도
|
CA2784793A1
(en)
|
2009-12-21 |
2011-07-21 |
Ambrx, Inc. |
Modified bovine somatotropin polypeptides and their uses
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
JP5998060B2
(ja)
|
2010-03-04 |
2016-09-28 |
マクロジェニクス,インコーポレーテッド |
B7−h3と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
|
CA2791841C
(en)
|
2010-03-05 |
2023-01-03 |
Rigshospitalet |
Chimeric inhibitor molecules of complement activation
|
PT3290428T
(pt)
|
2010-03-31 |
2021-12-27 |
Gilead Pharmasset Llc |
Comprimido compreendendo 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2h)-il)¿4¿fluoro¿3¿hidroxi¿4¿metiltetrahidrofuran¿2¿il)metoxi) (fenoxi)fosforil)amino)propanoato de (s)- isopropil cristalino
|
US8563530B2
(en)
|
2010-03-31 |
2013-10-22 |
Gilead Pharmassel LLC |
Purine nucleoside phosphoramidate
|
WO2011143274A1
(en)
|
2010-05-10 |
2011-11-17 |
Perseid Therapeutics |
Polypeptide inhibitors of vla4
|
CN102711871A
(zh)
|
2010-06-16 |
2012-10-03 |
麦德托尼克公司 |
用于稳定药物递送装置中的药物的阻尼系统
|
WO2011161644A1
(en)
|
2010-06-24 |
2011-12-29 |
Panmed Ltd. |
Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
FI3572091T3
(fi)
|
2010-08-17 |
2024-03-01 |
Ambrx Inc |
Muokattuja relaksiinipolypeptidejä ja niiden käyttötapoja
|
AR083006A1
(es)
|
2010-09-23 |
2013-01-23 |
Lilly Co Eli |
Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
|
BR112013008078A2
(pt)
|
2010-10-05 |
2016-06-14 |
Novartis Ag |
tratamentos de infecção por vírus da hepatite c
|
KR20130120481A
(ko)
|
2010-10-08 |
2013-11-04 |
노파르티스 아게 |
술파미드 ns3 억제제의 비타민 e 제제
|
CN105381450A
(zh)
|
2010-11-30 |
2016-03-09 |
诺华有限公司 |
丙型肝炎病毒感染的新疗法
|
PT3042910T
(pt)
|
2010-11-30 |
2019-04-16 |
Gilead Pharmasset Llc |
2'-espiro-nucleósidos para utilização na terapia da hepatite c
|
JP2014509628A
(ja)
|
2011-03-31 |
2014-04-21 |
ノバルティス アーゲー |
C型肝炎ウイルス感染症を治療するためのアリスポリビル
|
TW201247216A
(en)
|
2011-04-01 |
2012-12-01 |
Novartis Ag |
Treatment for infection with Hepatitis B virus alone or in combination with Hepatitis delta virus and associated liver diseases
|
MA35029B1
(fr)
|
2011-04-13 |
2014-04-03 |
Novartis Ag |
Traitement de l'infection par le virus de l'hépatite c avec l'alisporivir
|
CN103930440A
(zh)
|
2011-07-01 |
2014-07-16 |
拜耳知识产权有限责任公司 |
松弛素融合多肽及其用途
|
WO2013024156A2
(en)
|
2011-08-17 |
2013-02-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
|
WO2013024158A1
(en)
|
2011-08-17 |
2013-02-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
|
EP2760461A1
(en)
|
2011-09-27 |
2014-08-06 |
Novartis AG |
Alisporivr for treatment of hepatis c virus infection
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
JP2015509980A
(ja)
|
2012-03-14 |
2015-04-02 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Hcv−hiv同時感染患者集団のhcv感染症を治療するための併用療法
|
JP2015512900A
(ja)
|
2012-03-28 |
2015-04-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
特別な患者の遺伝子亜型分集団のhcv感染症を治療するための併用療法
|
BR112014030278A2
(pt)
|
2012-06-08 |
2017-06-27 |
Sutro Biopharma Inc |
anticorpo, e, composição.
|
EP3135690A1
(en)
|
2012-06-26 |
2017-03-01 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
CN102716469B
(zh)
*
|
2012-07-07 |
2013-09-11 |
北京三元基因工程有限公司 |
干扰素α的干粉吸入剂
|
WO2014033266A1
(en)
|
2012-08-31 |
2014-03-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
|
AU2013308494B2
(en)
|
2012-08-31 |
2018-03-01 |
Sutro Biopharma, Inc. |
Modified amino acids comprising an azido group
|
US20140205566A1
(en)
|
2012-11-30 |
2014-07-24 |
Novartis Ag |
Cyclic nucleuoside derivatives and uses thereof
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
WO2015006555A2
(en)
|
2013-07-10 |
2015-01-15 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
AU2014311827B2
(en)
|
2013-08-27 |
2017-09-14 |
Gilead Sciences, Inc. |
Combination formulation of two antiviral compounds
|
WO2015054658A1
(en)
|
2013-10-11 |
2015-04-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
US9388239B2
(en)
|
2014-05-01 |
2016-07-12 |
Consejo Nacional De Investigation Cientifica |
Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
|
ES2824028T3
(es)
|
2014-08-19 |
2021-05-11 |
Biogen Ma Inc |
Método de PEGilación
|
WO2016065326A2
(en)
|
2014-10-24 |
2016-04-28 |
Bristol-Myers Squibb Company |
Modified fgf-21 polypeptides and uses thereof
|
CN108135979A
(zh)
|
2015-11-03 |
2018-06-08 |
豪夫迈·罗氏有限公司 |
Hbv衣壳组装抑制剂和干扰素的组合疗法
|
GEP20227398B
(en)
|
2016-04-15 |
2022-07-25 |
Macrogenics Inc |
Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
|
BR112018076437A2
(pt)
*
|
2016-06-20 |
2019-10-01 |
Ambrx Inc |
interferon porcino peguilado e seus métodos de utilização
|
WO2018087345A1
(en)
|
2016-11-14 |
2018-05-17 |
F. Hoffmann-La Roche Ag |
COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
|
SG11201907209QA
(en)
|
2017-02-08 |
2019-09-27 |
Bristol Myers Squibb Co |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
EP3849614B1
(en)
|
2018-09-11 |
2023-12-20 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and their uses
|
EP3867265A1
(en)
|
2018-10-19 |
2021-08-25 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
WO2020160322A1
(en)
|
2019-01-30 |
2020-08-06 |
Horizon Pharma Rheumatology Llc |
Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
|
WO2020168017A1
(en)
|
2019-02-12 |
2020-08-20 |
Ambrx, Inc. |
Compositions containing, methods and uses of antibody-tlr agonist conjugates
|
JP2023517595A
(ja)
|
2020-03-11 |
2023-04-26 |
アンブルックス,インコーポレイテッド |
インターロイキン-2ポリペプチド結合物およびその使用方法
|
CA3190606A1
(en)
|
2020-08-20 |
2022-02-24 |
Ambrx, Inc. |
Antibody-tlr agonist conjugates, methods and uses thereof
|
IL307282A
(en)
|
2021-04-03 |
2023-11-01 |
Ambrx Inc |
Antidote conjugates against HER2 and their applications
|